glp-1 medications and surgery Patients should disclose drug usage before surgery, medical experts say What Patients Need to Know

Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G

biophysical Res

Based on Phase 2 trial data, Retatrutide achieved 24.2% weight loss versus tirzepatide's 20.9% (at a longer 72-week endpoint)

To track progress, take baseline photos under consistent lighting, at monthly intervals, and from multiple angles

Mike holds an Ornamental Horticulture degree, C-27 Landscape Contractor and D-49 Tree Service Contractor licenses, and Permaculture Design, California Naturalist, International Certified Professional Pond Contractor, and Pond Building certifications

This increases patient convenience and treatment adherence